KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Other Non-Current Assets (2016 - 2025)

BeOne Medicines (ONC) has disclosed Other Non-Current Assets for 10 consecutive years, with $161.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $161.7 million in Q2 2025 year-over-year; TTM through Jun 2025 was $161.7 million, a N/A change, with the full-year FY2023 number at $125.4 million, up 66.89% from a year prior.
  • Other Non-Current Assets was $161.7 million for Q2 2025 at BeOne Medicines, up from $125.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $173.4 million in Q1 2023 to a low of $3.9 million in Q2 2022.
  • A 4-year average of $57.8 million and a median of $9.1 million in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: tumbled 60.32% in 2022, then skyrocketed 2391.61% in 2023.
  • BeOne Medicines' Other Non-Current Assets stood at $6.9 million in 2021, then skyrocketed by 991.67% to $75.1 million in 2022, then skyrocketed by 66.89% to $125.4 million in 2023, then grew by 29.0% to $161.7 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Other Non-Current Assets are $161.7 million (Q2 2025), $125.4 million (Q4 2023), and $173.4 million (Q1 2023).